key: cord-1049978-twgustcm
authors: Mehta, Poonam; Sarkar, Saumya; Ghoshal, Ujjala; Pandey, Ankita; Singh, Ratender; Singh, Dharamveer; Vishvkarma, Rahul; Ghoshal, Uday Chand; Maurya, Ranjeet; Pandey, Rajesh; Ramachandran, Ravishankar; Bhadury, Punyasloke; Kundu, Tapas K; Rajender, Singh
title: Severe Acute Respiratory Syndrome Coronavirus-2 genome sequence variations relate to morbidity and mortality in Coronavirus Disease-19
date: 2021-05-24
journal: bioRxiv
DOI: 10.1101/2021.05.24.445374
sha: 8cce6d9a9286e42254ce624e0fc3b0a6fd7b5e23
doc_id: 1049978
cord_uid: twgustcm

Outcome of infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) may depend on the host, virus or the host-virus interaction-related factors. Complete SARS-CoV-2 genome was sequenced using Illumina and Nanopore platforms from naso-/oro-pharyngeal ribonucleic acid (RNA) specimens from COVID-19 patients of varying severity and outcomes, including patients with mild upper respiratory symptoms (n=35), severe disease ad-mitted to intensive care with respiratory and gastrointestinal symptoms (n=21), fatal COVID-19 outcome (n=17) and asymptomatic (n=42). Of a number of genome variants observed, p.16L>L (Nsp1), p.39C>C (Nsp3), p.57Q>H (ORF3a), p.71Y>Y (Membrane glycoprotein), p.194S>L (Nucleocapsid protein) were observed in similar frequencies in different patient subgroups. However, seventeen other variants were observed only in symptomatic patients with severe and fatal COVID-19. Out of the latter, one was in the 5’UTR (g.241C>T), eight were synonymous (p.14V>V and p.92L>L in Nsp1 protein, p.226D>D, p.253V>V, and p.305N>N in Nsp3, p.34G>G and p.79C>C in Nsp10 protein, p.789Y>Y in Spike protein), and eight were non-synonymous (p.106P>S, p.157V>F and p.159A>V in Nsp2, p.1197S>R and p.1198T>K in Nsp3, p.97A>V in RdRp, p.614D>G in Spike protein, p.13P>L in nucleocapsid). These were completely absent in the asymptomatic group. SARS-CoV-2 genome variations have a significant impact on COVID-19 presentation, severity and outcome.

Coronavirus Disease-19 began in December 2019 in Wuhan City, the capital of Hubei province, China and led to the current pandemic that devastated the whole World. At the time of writing, 90,086,549 people in the world were infected with the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), of whom 1,934,939 (2.1%) had died. Interestingly, 85% of the subjects infected with the SARS-CoV-2 virus remain asymptomatic; of the remaining 15% symptomatic patients, about a third develop severe disease. Interestingly, both the morbidity and mortality rates differ across countries with mortality being as high as 15% in some countries and as low as 0% in others 1 https://coronavirus.jhu.edu/data/mortality (accessed on the 20 th Dec. 2020). The factors associated with variations in the outcome of SARS-CoV-2 infection remain largely unknown. In different geographical locations, variations in SARS-CoV-2 genome have been shown previously. Whereas the "A" (the ancestral type such as the bat coronavirus) and "C" are prevalent in the United States of America and Europe, the "B" subtype has been shown to be prevalent in East Asia 2, 3 Earlier, we proposed the following factors that might predict the severity and outcome of SARS-CoV-2 infection; (A) host factors 4,5 : (i) age of the patients, (ii) presence of co-morbid illness, (iii) variation in the host's immune response to the virus due to difference in degree of T regulatory response (hygiene hypothesis), (iv) Bacillus Calmette-Guerin (BCG) vaccination, (v) variation in the gut microbiota 6, 7 ; (B) agent (viral) factors: (i) viral load, and (ii) viral genome sequences. In our earlier study, we found that there was no difference in viral load among patients with and without gastrointestinal (GI) symptoms, the presence of which was independently associated with severe COVID-19 5 . Some studies focusing on the viral genome variations have reported that the variability in the symptoms could be linked to a few 4 variations in the viral genome 8,9 . However, such studies are based on secondary analysis of data obtained from Global Initiative on Sharing Avian Influenza Data (GISAID) database 10 , which is prone to variations in the reporting of symptoms, their type and degree and the eventual outcome of the disease.

Among factors that could affect COVID-19 presentation, severity and eventual outcome, viral genome variations remain one of the most prominent and interesting factors. We undertook the whole genome sequencing of SARS-CoV-2 in nasopharyngeal swab samples from these patients and compared it with the reference genome sequence to investigate the relationship between SARS-CoV-2 genome variations and COVID-19 severity. We found that while some variations were shared across these classes, a number of mutations were more frequent in the symptomatic class and were completely absent in the specimens obtained from asymptomatic patients.

The experimental protocols were approved by the Institutional Ethics Committee of Sanjay Gandhi Postgraduate Institute of Medical Sciences. All methods were carried out in accordance with relevant guidelines and regulations. Informed consents were obtained from all participants. The samples were obtained from the patients diagnosed suffering from COVID-19 in a referral laboratory of a university hospital in northern India and from the patients admitted with the disease to the same hospital. All samples were collected between May and August, 2020. We undertook genome sequencing from naso-, oro-pharyngeal swab samples on a total of 115 COVID-19 patients with fatal disease (n=17), severe disease with gastrointestinal symptoms (GIS; n=21), mild disease with nasopharyngeal symptoms (NS; n=35), and asymp-5 tomatic infection (AS; n=42). The severity of the COVID-19 was assessed as described previously-(i) critical (required ventilator), (ii) severe (needed oxygen), (iii) moderate (although pneumonia was present, the patient did not require oxygen), and (iv) mild (only upper respiratory symptoms) 11 . The gastrointestinal symptoms included anorexia, nausea, vomiting, abdominal pain and diarrhea.

RNA was isolated using QIAamp Viral RNA kit (Qiagen, Hilden, Germany) using mini spin procedure according to the manufacturer's instructions. RNA was quantified using nanodrop, followed by conversion of 50ng RNA into cDNA using high-capacity cDNA synthesis kit (Applied Biosystems, Foster City, California, USA). The first strand of cDNA was synthesized using random hexamers. SARS-CoV-2 detection was performed by quantitative real time PCR using Taqpath COVID-19 combo kit (Applied Biosystems, ThermoFisher Scientific, Foster City, California, USA). The kit uses spike (S) and nucleocapsid (N) protein regions for detection, which offer higher specificity due to lower risk of mutation in these regions.

Samples with Cycle threshold (Ct) values of less than 28 were used for genome sequencing.

cDNA synthesized in the above step was used for amplification of the SARS-CoV-2 genome using primers recommended by ARTIC Webpage: https://github.com/artic-network/artic-ncov2019/blob/master/primer_schemes/nCoV-2019/V3/nCoV-2019.tsv. The primers were pooled in four groups for optimal performance (Table 1) .

PCR amplification of SARS-CoV-2 genome was carried out using AmpliTaq Gold 

Amplicons generated by PCR in 4 reactions were pooled together and purified using 0.1X AMPure beads. 100ng of the pooled amplicons was used for subsequent sequencing using Miseq data analysis 7 The raw reads generated on MiSeq were checked for quality using FASTQC (version 0.11.8, Babraham Institute, Cambridge, UK). Trimgalore application was used to trim the reads containing bad quality and a minimum length of 40 base pairs was set as the threshold for the reads. The reads were converted from bam to fastq using bam2fastq (version 2.29) to align to the SARS-CoV-2 genome. HISAT2 was used to map the reads to the viral genome.

Consensus fasta sequence was generated using samtools (version 1.9) and BCFtools on SARS-CoV-2 aligned files. The variants in the samples were called using BCFtools and VarScan.

The amplicons not covered in the first sequencing on Miseq were re-amplified separately and subjected to sequencing using nanopore sequencing technology. After purification for size Massachusetts, USA). The ligation mix was incubated at room temperature for 15 mins followed by AMPure bead purification. The purified product was quantified using Qubit dsDNA HS assay kit and 50ng of the product was further taken for adaptor ligation using adapter mix II and quick T4 DNA ligase (Cat. No. E6056S, New England Biolabs, Ipswich, Massachusetts, USA) followed by 20 mins incubation at room temperature. After adaptor ligation, purification was done using AMPure beads and short fragment buffer. Library was 8 quantified using qubit dsDNA HS assay kit (Invitrogen, Carlsbad, California, USA) and 15ng of the library was used for sequencing. Sequencing flow cell was primed using flow cell priming kit (EXP-FLP002), and sequencing was performed on MinION Mk1B platform (Oxford Nanopore Technologies, Oxford, UK).

The raw Fast5 and Fastq files generated in MinKnow were basecalled and demultiplexed using Guppy basecaller (Version v.4.0.15). The ARTIC pipeline was used for bioinformatics analysis, which involved read filtering, primer trimming, amplicon coverage normalisation, variant calling and consensus building (https://artic.network/ncov-2019/ncov2019bioinformatics-sop.html).

For molecular phylogeny analysis, 3168 full length SARS-CoV-2 genome sequences submitted from India were downloaded from the GISAID database (November, 2020). Representatives of our SARS-CoV-2 genome sequences (25 types) were considered as part of this analysis. The reference genome of the SARS-Cov-2 RNA virus (NC_045512) was also considered in this study. All the genome sequences (3181) were subsequently aligned in MAFFT (https://mafft.cbrc.jp/alignment/server/). Based on the alignment, only 3020 full length genome sequences were further considered for downstream analyses. Twenty-five representative sequences we generated were subjected to maximum likelihood (ML) phylogeny based on Juke-Cantors model with bootstrap replicates (1000) in MEGA v7.0 12 . For the alignment containing 3020 full length genome sequences, nucleotide composition, codon usage, singletons and CpG were calculated in MEGA v7.0. Molecular phylogeny of the 3020 genome se-9 quences were undertaken using NJ approach while taking into account the number of synonymous substitutions per synonymous site.

Specific amino acid changes as a result of a mutation were annotated using SnpEff (version 4.5) 13 . For this, the reference sequence of SARS-CoV-2 from Wuhan was used in Spike protein, p.13P>L in nucleocapsid). These mutations were completely absent in the asymptomatic category of the patients. However, the occurrence and frequency of these mutations did not differ significantly across three categories (dead, GI, NS) of the symptomatic patients.

Based on molecular phylogeny, the ML tree consisting of SARS-CoV-2 genomes we generated revealed two main clusters -Clade I and II (Fig. 1) . The Clade I consisted of 21 genome sequence types while the Clade II consisted of the remaining 4 types. Divergent sub-clades were encountered in both the clades with strong bootstrap support.

In this study, the robust alignment consisted of 3020 full-length genome sequences with no ambiguity was undertaken. The relative synonymous codon usage (RSCU) and basic nucleotide composition (A%, U%, C%, and G%), AU and GC contents have been detailed in Supplementary Tables 1 and 2 respectively. Based on codon analysis, most of them tend to exhibit U ending. Interestingly, encountered CpGs were low (1640) based on the analysis of 1 1

Multiple alignment of viral protein sequences across the SARS, MERS and other virus families showed that the amino acid residues were conserved across the SARS family only (Fig   3) . Most of the amino acid residues were not conserved in other viruses such as MERS. This showed significant changes in the protein sequences and the divergence of the SARS family from other viruses.

We observed three mutations in the Nsp2 protein (C1121T, G1274T, and C1281T) in our samples (Table 2) , which caused P106S, V157F, A159V amino acid substitutions, respectively. A159V changed into the same group of amino acid while V157F changed aliphatic to aromatic group. We mapped these positions in the full-length protein structure model (experimental structure not available). Out of two mutations present in the C-terminal loop region, V157F (valine to phenylalanine) may affect the structure-function while A159V

(alanine to valine) may not affect protein function (Fig. 4) . Also Nsp2 secondary structure composition suggests it to have large loop region between the N-terminal and the C-terminal, which may cause fluctuations in the structure. [15] . DUF3655 and NAR domains do not have any experimental structure, but it is available for the ADP ribose domain [PDB: 6W6Y]. Therefore, we modelled the 1 2 structure and mapped the location of the mutated residues. Two mutated residues (D226D and V253V) in the ADP ribose domain were present in the pocket and one (N305N) was present near the pocket (Fig. 4) . The NAR domain had two domains with two mutations (S1197R and T1198K) present in the loop region of domain 1. Missense mutation T1198K substituted threonine (polar, neutral) with lysine (positively charged). The predicted active region is present between both the domains and both residues were present near the pocket.

T1198K substitution is very likely to affect the structure-function of the protein. Both the mutations (S1197R and T1198K) in the Nsp3 protein lie in the nucleic acid binding domain and replaced polar uncharged amino acids with positively charged amino acids, suggesting enhanced interaction with viral genome due to the addition of a positively charged amino acid [16] .

The RNA-directed RNA polymerase (RdRp) is responsible for replication and transcription of the viral RNA genome. The experimental structure is available with Nsp7 and Nsp8 complex, they activate and confer processivity to the RNA-synthesizing activity of the polymerase [17, 18] . The mutation at position A97V has been previously shown to cause a change in secondary structure in RdRp enzyme [19] . The spike glycoprotein had an important point mutation at position D614G. Aspartic amino acid (D) is acidic and polar in nature while glycine is aliphatic and nonpolar. This mutation has been most widely investigated and affects spike protein conformation in a way to enhance the receptor binding ability of the spike protein [7, 20] . . Since these solved structural regions do not cover the mutations observed, we modeled the full length structure to map the position of mutated residues (P13L and S194L). P13L may not affect structure but S194L results in a different nature of amino acid, which may affect protein function (Fig 4) . Both amino acids are present in the loop region.

In this study, we aimed at investigating the relationship between the SARS-CoV-2 genome sequence variations and COVID-19 severity. Among a number of mutations across the viral genome, a few clustered in symptomatic patients and were completely absent in asymptomatic patients. This included a 5'UTR mutation (g.241C>T), eight synonymous mutations (p.14V>V and p.92L>L in Nsp1 protein, p.226D>D, p.253V>V and p.305N>N in Nsp3, p.34G>G and p.79C>C in Nsp10 protein, p.789Y>Y in Spike protein), and eight nonsynonymous mutations (p.106P>S, p.157V>F and p.159A>V in Nsp2, p.1197S>R and p.1198T>K in Nsp3, p.97A>V in RdRp, p.614D>G in Spike protein, p.13P>L in nucleocapsid). Sequence comparison with other coronaviruses showed a strong conservation of these amino acid residues within the SARS family of viruses, suggesting their critical role in protein function in this family. Some of the mutations we observed have been previously linked with disease severity on the basis of genome sequences downloaded from the public databases. For example, g.241C>T mutation in the 5'UTR, A97V in the RdRp protein, P13L in the nucleocapsid protein, D614G mutation in the spike protein, S1197R and T1198K in the Nsp3 protein were found more often in hospitalized patients/severe disease in comparison to 1 4 those with mild disease 9, 15, 16 . Comparison of the genotype frequency of five most important mutations across China, Italy, USA, UK and India showed significant changes in the frequency of alternate nucleotides at g.241C>T and p.614D>G positions (Fig 5) .

Out of the mutations we observed in the symptomatic class only, D614G has been the most commonly discussed with respect to virus infectivity and virulence. The 614G form of the spike protein is more likely to assume an open conformation than the ancestral 614D form, resulting in improved binding to the ACE2 receptor. In human epithelial cells, the 614G variant replicated more efficiently than the 614D variant. Accordingly, D614G mutation has been found to increase transmissibility 17, 18 and patients with 614G associated SARS-CoV-2 have been found to have higher viral load and show lower Ct values 18 . Interestingly, in studies on hamsters despite variant infection ratios of upto 9 times in favour of 614D, 614G replicated to higher titres and outcompeted the D form and the 614G variant also seemed to be more stable in comparison to the ancestral 614D variant 19 . However, 614G did not cause more severe disease than the ancestral 614D variant 20 . We found that 614D is seen more commonly in the symptomatic patients with a more severe form of the disease, and was completely absent in the asymptomatic patients, though we did not find it to further differ as per severity in the variant towards the end of the first COVID-19 wave could be behind the second wave characterized by a much faster spread than the first wave.

D614G has been the most controversial mutation with respect to its effect on virulence.

While 614G has been established to result in higher infectivity 19 , it has not been related to higher severity 20 . At least three studies based on data from public databases suggest 614G to correlate with higher severity. Toyoshima et al, (2020) compared genomes from the GISAID database and found that 614G showed positive correlation with fatality 21 . In another similar study, Biswas and Mudi (2020) found 614G to correlate with a more severe form of the disease 9 . In yet another study, Nagy et al. (2021) downloaded genome sequences and classified the patients into mild outcome, hospitalized and severe outcome groups, the comparison of which showed increased severity with 614G 16 . Nevertheless, all these studies are based on data from public databases and should not be taken as independent evidence supporting the correlation of 614G with a more severe disease. The reliability of the information provided in the database and further in-depth details including the types of symptoms, level of morbidity and the eventual mortality remain unreliable for conducting such studies with high confidence. In the instances where they have been compared, the conclusions regarding their impact on COVID-19 severity appear over-stated. We observed the 614D variant only in the symptomatic patients. Interestingly, a higher severity in the 614D variant has been supported by original investigations in the lone study with good sample size 18 and 614G has been ruled out for a higher severity 20 .

A number of mutations we observed in the symptomatic patients were found to mildly or significantly affect protein function by in-silico assays. A97V has been previously shown to cause a change in secondary structure in RdRp enzyme 22 . Both the mutations (S1197R and Based on the NJ phylogeny of 3020 genome sequences from India, the distinct subclade consisting of genome data represented by type 2E along with eight genome sequences from patients of Maharashtra and Gujarat reflected connectivity of transmission with possible signature of emerging divergence in these SARS-CoV-2 genomes. In India at an early stage, various SARS-CoV2 clusters inclusive of A2a, A3, and A4 were identified. A4 cluster was more prevalent in India 12 . Comparison of the latest mutation data with these clusters revealed high frequency of mutations, such as nucleocapsid p.13P>L; nsp3 p.1197S>R; p.1198T>K; spike p.614D>G; RdRP (A97V), nsp2 p.159A>V; Orf3a p.57Q>H 12 .

Among other viral variants, ∆ 382 reported in Singapore associated with lower odds of developing hypoxia requiring supplemental oxygen compared with infection with the wild-type virus 24 . To prove that the viral genotype could affect infectivity, Yao et al, (2020) undertook functional characterization of mutations observed in their viral isolates. Very interestingly, these viral isolates showed significant variation in the cytopathic effects and viral load when checked by infecting Vero-E6 cells 25 . In another study on data from public databases, Ai- [26] [27] [28] . Of particular note are metabolic syndrome, cardiac diseases and respiratory pre-disposition, which adversely affect the eventual outcome in these patients 29, 30 . Another important factor that has been suggested to affect COVID-19 disease severity is the gut microbiome 5 . Interestingly, a gut-lung axis has been suggested to influence the lung's susceptibility to viral infections 31 . We did not find a significant difference in the age of symptomatic patients from asymptomatic; nevertheless, the lack of adjustment of data for patient age, host genetic factors, microbiome and comorbidities is a limitation of our study. 1 8 In conclusion, the comparison of virus genotype across symptomatic and asymptomatic COVID-19 patients identified a clustering of unique viral genome variants in the symptomatic classes, which were completely absent in the asymptomatic class. However, these variants did not differ in frequency across the symptomatic classes showing no correlation with the degree of morbidity within the symptomatic class. Out of these variants, we would like to emphasize on the potential importance of the mutations observed in all three categories of the symptomatic patients. Among these g. 241C>T 

Morbidity and mortality trends of Covid 19 in top 10 countries

Phylogenetic network analysis of SARS-CoV-2 genomes

Variant analysis of SARS-CoV-2 genomes

The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review

The Spectrum of Gastrointestinal Symptoms in Patients With Coronavirus Disease-19: Predictors, Relationship With Disease Severity, and Outcome

Gut microbiota and Covid-19-possible link and implications

Alterations in gut microbiota of patients with COVID-19 during time of hospitalization

Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of COVID-19 and biomedical interventions

Genetic variation in SARS-CoV-2 may explain variable severity of COVID-19

SARS-CoV-2 genetic variations associated with COVID-19 severity

COVID-19 severity scoring tool for low resourced settings

Integrated genomic view of SARS-CoV-2 in India

A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3

The EMBL-EBI search and sequence analysis tools APIs in 2019

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Different mutations in SARS-CoV-2 associate with severe and mild outcome

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity

Spike mutation D614G alters SARS-CoV-2 fitness

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

SARS-CoV-2 genomic variations associated with mortality rate of COVID-19

Identification of novel mutations in RNA-2 7

RNA polymerases of SARS-CoV-2 and their implications on its protein structure

Potentially adaptive SARS-CoV-2 mutations discovered with novel spatiotemporal and explainable AI models

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

Patient-derived mutations impact pathogenicity of SARS-CoV-2

COVID-19 and comorbidities: a systematic review and metaanalysis

Clinical Characteristics of Coronavirus Disease 2019 in China

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Comorbidity and its Impact on Patients with COVID-19. SN Comprehensive Clinical Medicine, 1-8. Advance online publication

Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies

COVID-19 and the gut microbiome: more than a gut feeling